3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
11
Gastrointestinal
5
Thoracic
4
Sarcoma
2
Gynecologic
2
Dermatologic
2
Breast
2
Plasma cell
1
Other hematologic neoplasm
1
Other
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Endocrine
1
Classical hematology
1
CNS
1
Conditions
Neuroendocrine Tumors
4
Adenoma, Islet Cell
2
Tuberous Sclerosis
1
Neoplasms
1
Gastroenteropancreatic Neuroendocrine Tumors
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Carcinoid Tumor
1
Interventions
Everolimus
5
Sunitinib
4
lutetium Lu 177 dotatate
2
PM 01183
2
Octreotide
2
Doxorubicin
2
trifluridine tipiracil drug combination
1
telotristat ethyl
1
repotrectinib
1
pralsetinib
1
pegfilgrastim
1
pasireotide
1
motesanib diphosphate
1
epothilone B
1
dactolisib
1
copper dotatate CU-64
1
batifiban
1
avelumab
1
alectinib
1
Temozolomide
1
TKM-080301
1
Surveys and Questionnaires
1
SNX-5422
1
Referral and Consultation
1
Radiomics
1
Quality of Life
1
Patient Reported Outcome Measures
1
Oxaliplatin
1
Molecular Diagnostic Techniques
1
Lutetium-177
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Injections
×
NET
×
Clear all
NCT04837885
2025-07-23
LUTARTERIAL
University Hospital, Bordeaux
Phase 2
Recruiting
23 enrolled